Oligonucleotide Therapeutics Society
Recent Articles2026-08-24T06:57:48+00:00
16July, 2025

OTS Member Highlight – Masad Damha, PhD

For Masad Damha, falling in love with science was easy. Growing up in Managua, Nicaragua, his high school teachers encouraged scientific exploration, curiosity, and experimentation, such as processing vegetable oil into soap, producing hydrogen and oxygen from water via electrolysis, and determining the gravitational force constant using a pendulum. ...

1July, 2025

Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease

Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, and more than 200,000 are at risk of inheriting it. The fatal disease often leaves a devastating family legacy, as ...

3June, 2025

NanoCas: A Newly Identified Compact Nuclease May Expand CRISPR’s Reach

The revolutionary CRISPR-Cas system has proven to be a precise method for genome editing, showing great promise in tackling genetic disorders. However, clinical trials for CRISPR-based treatments have faced delivery challenges due to the large size of the editing system. In the quest to overcome these limitations, researchers recently ...

13May, 2025

OTS Member Highlight – Holly Kordasiewicz, PhD

Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed neurodegenerative diseases gradually and relentlessly ...

25February, 2025

2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases

In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in 30 years — include an oligonucleotide therapy for blood cancer, an antisense oligonucleotide shown to significantly drop triglyceride levels, and ...

Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease

July 1st, 2025|Categories: Perspectives on Current Science|

Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, ...

Get the latest news!

  • Category

Go to Top